Latest From Cerapedics Inc.
Stryker CFO retires and Osiris Therapeutics CEO resigns, as SpineGuard and Tandem Diabetes Care expand management teams.
The case would have tested whether manufacturers could be held liable if an FDA-approved device injured a patient when the product was employed for an off-label, unapproved use. The Oklahoma Federal Court and the 10th Circuit Court of Appeals had both previously ruled in industry’s favor.
Amidst low growth and a potential rebound in the $9 billion global spine market, the pure-play spine companies, including NuVasive, Globus, K2M and LDR, continue to outperform and grab share from the diversified giants. Medtech Insight founder and former CEO Sharon O'Reilly reports on these companies and more from the 2015 North American Spine Society (NASS) conference in Chicago, where the latest news centered around ancillary approaches to fusion, patient-specific tools, robotics, biologics, expandable cages, MIS and cervical discs.
Cerapedics' i-Factor peptide-enhanced bone graft will be used to treat degenerative cervical disc disease, the first bone graft product PMA-approved for that indication, the company says.
- Large Molecule
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- CeraPedics LLC
- North America
- Parent & Subsidiaries
- Cerapedics Inc.
- Senior Management
Glen A Kashuba, CEO
Drew Trivisonno, CFO
Jerome Connor, PhD, VP, R&D
Jeffrey G Marx, PhD, Pres. & COO
Andrew W Barnes, VP, US Sales
Tommy Vollmar, VP, Mktg.
Patrick O'Connor , VP, Clinical & Mkt. Dev.
- Contact Info
Phone: (303) 974-6275
11025 Dover St., Ste. 1600
Westminster, CO 80021
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.